- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04315064
Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults With Recurrent Medulloblastoma
June 20, 2023 updated by: David Ilan Sandberg, The University of Texas Health Science Center, Houston
Infusion of Panobinostat (MTX110) Into the Fourth Ventricle or Tumor Resection Cavity in Children and Adults With Recurrent Medulloblastoma: A Pilot Study
The purpose of this study is to establish the safety of infusions of panobinostat (MTX110) into the fourth ventricle of the brain or tumor resection cavity in patients with recurrent medulloblastoma and to assess the antitumor activity of simultaneous infusions of panobinostat (MTX110) into the fourth ventricle of the brain or resection cavity in patients with recurrent medulloblastoma based upon MRI scans and lumbar cerebrospinal fluid (CSF) cytology.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
5
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: David IIan Sandberg, MD
- Phone Number: (713) 500-7370
- Email: David.I.Sandberg@uth.tmc.edu
Study Contact Backup
- Name: Bangning Yu
- Phone Number: (713) 500-7363
- Email: Bangning.Yu@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas Health Science Center at Houston
-
Contact:
- David Sandberg, MD
- Phone Number: 713-500-7370
- Email: David.I.Sandberg@uth.tmc.edu
-
Contact:
- Bangning Yu
- Phone Number: (713) 500-7363
- Email: Bangning.Yu@uth.tmc.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 80 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis: Patients with histologically verified medulloblastoma with recurrence or progression involving anywhere in the brain and/or spine.
- Patient must have either measurable or evaluable tumor as assessed by MRI of the brain and total spine
- An implanted catheter in the fourth ventricle or posterior fossa tumor cavity attached to a ventricular access device or agreement to have one placed.
- A minimum of 7 days between last dose of systemic chemotherapy and/or radiation therapy and first infusion of chemotherapy into fourth ventricle
- Life expectancy of at least 12 weeks in the opinion of the principal investigator
- Lansky score of 50 or greater if ≤16 years of age or Karnofsky score of 50 or greater if > 16 years of age
- Existing neurological deficits must have been stable for a minimum of 1 week prior to study enrollment
- Patients must have recovered from the acute toxic effects of all prior anticancer chemotherapy
- Adequate bone marrow function defined by peripheral absolute neutrophil count (ANC) ≥ 500/µL, platelet count ≥ 50,000/µL (transfusion independent), and hemoglobin ≥ 9.0 gm/dL (may receive red blood cells(RBC) transfusions)
- Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent.
- Patient with prolonged QT interval on screening EKG will need cardiology consultation prior to enrollment
- Patients with abnormal liver function tests (ALT, Aspartate Aminotransferase(AST),or total bilirubin) will need gastroenterology consultation prior to enrollment
Exclusion Criteria:
- Enrolled in another treatment protocol
- Has received another investigational or chemotherapy agent or radiation therapy within 7 days prior to intraventricular chemotherapy infusions
- Evidence of untreated infection
- Pregnant or lactating women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment with MTX110
|
Patients will undergo surgery for maximum safe tumor resection with simultaneous placement of a ventricular access device (VAD) into the fourth ventricle or posterior fossa tumor resection cavity.The specific ventricular access device that will be placed is Medtronic Reference number 44102, "Medtronic CSF-Ventricular Reservoir Side Inlet, 18 mm.If a patient already has a ventricular access device in place and additional tumor resection is not required, then that patient can proceed with intraventricular chemotherapy infusions after study enrollment.
If the patient has metastatic disease in the brain and/or spine without resectable tumor in the posterior fossa, then only catheter and ventricular access device placement will be performed.Enrolled patients will receive 4 infusions per week of panobinostat (MTX110; 0.25 ml of 300 μM = 26.2
μg), per infusion into the ventricular access device for 6 consecutive weeks for a total of 24 infusions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with grade 3 through grade 5 new neurological adverse events that are related to study drug
Time Frame: 4 months post intervention
|
Anew neurological deficit will be defined as new cranial neuropathy, change in level of consciousness, motor weakness, gait change or cerebellar finding (ataxia, dysmetria, dysdiadochokinesis) and will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0
|
4 months post intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in disease progression as measured by an MRI
Time Frame: prior to first infusion; after last infusion (last infusion is about 6 weeks after the first infusion)
|
Change in disease progression as measured by an MRI
|
prior to first infusion; after last infusion (last infusion is about 6 weeks after the first infusion)
|
Change in disease progression as measured by lumbar CSF cytology
Time Frame: prior to first infusion; after last infusion (last infusion is about 6 weeks after the first infusion)
|
Change in disease progression as measured by lumbar CSF cytology
|
prior to first infusion; after last infusion (last infusion is about 6 weeks after the first infusion)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: David IIan Sandberg, MD, The University of Texas Health Science Center, Houston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 21, 2020
Primary Completion (Estimated)
December 30, 2025
Study Completion (Estimated)
December 30, 2025
Study Registration Dates
First Submitted
March 17, 2020
First Submitted That Met QC Criteria
March 17, 2020
First Posted (Actual)
March 19, 2020
Study Record Updates
Last Update Posted (Actual)
June 22, 2023
Last Update Submitted That Met QC Criteria
June 20, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-19-0939
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medulloblastoma
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingUntreated Childhood MedulloblastomaUnited States, Canada, Australia, New Zealand, Switzerland, Netherlands
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Ependymoma | Recurrent MedulloblastomaUnited States
-
University of California, San FranciscoWashington University School of Medicine; University of Washington; Pacific Pediatric... and other collaboratorsRecruitingMedulloblastoma | Medulloblastoma, Childhood | Medulloblastoma RecurrentUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
Sabine Mueller, MD, PhDMayo Clinic; Vyriad, Inc.; No More Kids With Cancer; The Matthew Larson Foundation...CompletedMedulloblastoma Recurrent | Atypical Teratoid/Rhabdoid Tumor | Medulloblastoma, Childhood, RecurrentUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingMedulloblastoma | Anaplastic MedulloblastomaUnited States, Canada, Puerto Rico, Australia, Netherlands
-
St. Jude Children's Research HospitalSt. Baldrick's FoundationCompletedMedulloblastomaUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Children's Neuro-Oncology Group (CNOG)UnknownMedulloblastoma, ChildhoodChina
-
St. Jude Children's Research HospitalEli Lilly and CompanyActive, not recruitingBrain Cancer | Brain Tumor | Medulloblastoma | Brain Tumor, Recurrent | CNS Tumor | Medulloblastoma Recurrent | CNS Cancer | Medulloblastoma, Non-WNT/Non-SHH | Brain Tumor, Pediatric | CNS Neoplasm | Brain Tumor, Refractory | Medulloblastoma, Non-WNT/Non-SHH, Group 3 | Medulloblastoma, Non-WNT/Non-SHH, Group 4United States
Clinical Trials on Treatment with MTX110
-
Luca SzalontayMidatech Pharma US Inc.CompletedDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma | Diffuse Pontine and Thalamic GliomasUnited States
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology Consortium; Midatech Pharma US Inc.CompletedDiffuse Intrinsic Pontine GliomaUnited States
-
Universidad Complutense de MadridRecruitingMalocclusion, Angle Class II | DistalizationSpain
-
Helsinki University Central HospitalActive, not recruitingto Omit Radioiodine Treatment Safely in Patients With Low -Risk Papillary Thyroid Cancer With Seize of 11-20mm
-
University Hospital, LilleMinistry of Health, France; Laboratoire français de Fractionnement et de BiotechnologiesTerminatedHeart FailureFrance
-
Odense University HospitalNovo Nordisk A/S; Department of Nephrology, Odense University Hospital; The A... and other collaboratorsRecruitingKidney Failure, Chronic | Kidney Injury | Risk Reduction | Contrast-induced NephropathyDenmark
-
University of Roma La SapienzaUnknownCoronary Artery DiseaseItaly
-
The Metis FoundationUnited States Army Institute of Surgical ResearchCompletedHypertrophic ScarUnited States
-
Medical University of GrazRecruitingCarpal Tunnel SyndromeAustria
-
Wroclaw Medical UniversityCompletedCaries,Dental | Aerosol DiseasePoland